BACKGROUND: Studies have demonstrated superior outcomes for adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) who are treated using pediatric versus adult therapeutic regimens. To the best of our knowledge, whether adult oncologists in the United States have adopted this approach to ALL in AYA patients is currently unknown. The objective of the current study was to provide a population-based description of ALL treatment patterns in AYA individuals over the past decade. METHODS: Data regarding AYA patients aged 15 to 39 years and diagnosed with ALL between 2004 and 2014 while living in the Greater Bay Area were obtained from the Greater Bay Area Cancer Registry (GBACR). Treating facilities were designated as pediatric or adult centers; induction treatment regimens were abstracted from registry text data fields. RESULTS: Of 304 patients diagnosed in the GBACR catchment region, complete treatment data were available for 229 (75%). The location of care was identified for 296 patients (97%) treated at 31 unique centers. Approximately 70% of AYA patients received induction therapy at an adult treatment center. All AYA patients who were treated at pediatric centers received pediatric ALL regimens. Among AYA patients treated by adult oncologists with complete treatment data, none received a pediatric regimen before 2008. Between 2008 and 2012, while the US Adult Intergroup C10403 pediatric-inspired ALL protocol was open to accrual, 31% of AYA patients treated by adult oncologists received pediatric regimens. This rate fell to 21% from 2013 through 2014. Adult facilities treating 2 AYA patients with ALL per year captured in the GBACR were more likely to administer pediatric regimens than lower volume centers (P 5.03). CONCLUSIONS: As of 2014, only a minority of AYA patients with ALL received pediatric ALL regimens at adult cancer centers. Cancer 2017;123:122-30.
INTRODUCTION
Over the past decade, a large body of research has focused on discrepancies in the treatment approach and survival of adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) treated in the pediatric versus adult setting. A multitude of retrospective analyses from US and European cooperative groups have concluded that, independent of traditional ALL risk factors, AYAs with ALL have markedly superior outcomes when treated by pediatric oncologists following pediatric treatment protocols. [1] [2] [3] [4] [5] In general, pediatric ALL regimens are more intensive and more highly regimented than adult regimens, most likely contributing to their improved success. 6 The intriguing findings from retrospective studies [1] [2] [3] [4] [5] have led many groups to prospectively consider the feasibility and outcomes of pediatric-inspired protocols administered to AYA patients with ALL by adult oncologists. [7] [8] [9] [10] [11] [12] [13] Recently, the preliminary results of US Intergroup Study C10403, the largest prospective evaluation of a pediatric treatment approach applied by adult oncologists to AYA patients with ALL, have been presented. 14 Among 318 AYA patients aged 17 to 39 years who were enrolled from 2007 through 2012, the 2-year event-free survival and overall survival rates were 66% and 78%, respectively, which was considerably higher than the event-free survival and overall survival rates of 34% and 46%, respectively, of historical controls treated on US adult cooperative group trials for ALL.
occurring malignancy in children, it occurs less frequently in adults, accounting for only 15% of all adult leukemia and 0.4% of adult cancer diagnoses in the United States. 15 A large percentage of ALL occurring in AYAs is treated in the community rather than at National Cancer Institute (NCI)-designated comprehensive cancer centers. 16 The pediatric-inspired regimens recommended for the treatment of ALL in AYA patients include drugs and therapeutic combinations that may not be routinely used in adult oncology practice; thus, the implementation of pediatricinspired regimens that require frequent and prolonged outpatient therapy may be daunting for adult oncologists who treat a paucity of patients with ALL each year. For example, the delivery of asparaginase throughout the treatment period is critical to the success of pediatric ALL regimens, but use of this agent requires familiarity with its potential toxicities. 17 The seminal finding that more AYA patients with ALL may be cured if treated with pediatric-inspired regimens is only meaningful if adult oncologists routinely and successfully adopt and adhere to these treatment protocols. Thus, to understand changes in the use of pediatricinspired ALL regimens over the past decade, we used facility-level data from a population-based cancer registry to describe treatment patterns of ALL in AYA patients among pediatric and adult oncologists.
MATERIALS AND METHODS
Data were abstracted from the population-based Greater Bay Area Cancer Registry (GBACR), a division of the California Cancer Registry (CCR) and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. The GBACR includes approximately 6.8 million residents of the 9-county Greater Bay Area (GBA) (Alameda, Contra Costa, Marin, Monterey, San Benito, San Francisco, San Mateo, Santa Clara, and Santa Cruz counties) who receive a cancer diagnosis within the counties, regardless of health insurance status or treating facility. Case selection included all AYA individuals aged 15 to 39 years at the time of their diagnosis of ALL (International Classification of Diseases for Oncology, 3rd Edition 18 codes 9826, 9835, 9836, 9811-9818, and 9837 as per SEER site recode for ALL), with diagnosis occurring between 2004 and 2014. Because GBACR data were used for this analysis, only residents of the GBA were included; individuals who resided outside of the GBACR counties but were treated in a facility within the GBA region were not included in the current analysis. Conversely, a small number of patients diagnosed in the GBA but receiving induction therapy outside of the GBACR were included because their treatment data were reported to the GBACR.
Patient and tumor characteristics were obtained from the GBACR (routinely collected for the registry via medical record abstraction), including age at diagnosis, sex, race/ethnicity, health insurance status at the time of initial diagnosis or treatment, and a previously developed composite measure of neighborhood socioeconomic status (SES) that incorporates US Census block group-level data regarding income, education, housing costs, and employment; patients were assigned to statewide SES quintiles based on their address at the time of their diagnosis. 19, 20 14 We reviewed all available GBACR facility-level reports for each patient. These facility-level reports reflect information reported to the GBACR from each facility, and normally are consolidated to the tumor level when reported to SEER. For each patient diagnosed in the GBA and captured in the GBACR, the initial ALL induction chemotherapy regimen was abstracted from a data text field. Treatment regimens included in the analysis were listed by name recorded in the registry (eg, "C9511," "hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone]," etc). Individuals with registry treatment text fields that included only therapeutic agents without the specific regimen name (eg, cyclophosphamide, vincristine, doxorubicin, or dexamethasone without mention of the specific regimen) were designated as unclear (neither adult nor pediatric) and were not coded as having received a specific regimen. Induction regimens were categorized as either adult or pediatric/pediatric-inspired ALL regimens. Adult ALL regimens included hyper-CVAD, 21 14 and the Linker regimen. 26 Pediatric/pediatric-inspired regimens included US Intergroup Trial C10403, 14 the Dana-Farber Cancer Institute pediatric-inspired regimen, 11 and any US pediatric cooperative group ALL regimen.
Physicians involved in the care of the patient (attending physician, medical oncologist, radiation oncologist, referring physician, follow-up physician, and up to 2 additional physicians) were recorded in the registry. The medical license numbers of all physicians listed for each patient were cross-referenced with CCR and GBACR physician databases to obtain the physician's medical specialty. The facility in which the induction treatment was administered (treatment setting) was designated as either a pediatric or adult setting. Patients receiving induction in a facility that reports to the GBACR as a stand-alone children's facility (cross-referenced with a list of Children's Oncology Group pediatric cancer centers 27 and children's hospitals 27 across California) were considered to have been treated in a pediatric setting. Patients receiving induction in a facility that does not treat children were considered to have been treated in an adult setting. Patients treated at institutions that treat both children and adults and do not report cancer cases from their pediatric and adult hospitals separately were identified as having been treated in a pediatric setting only if the treating physician was a pediatric oncologist. Cases in which the treatment setting (pediatric vs adult) could not be clarified through this methodology were considered to have an unidentifiable treatment setting and were not included in further analyses. Hospitals were classified by their affiliation with an NCI-designated cancer center, and facility AYA ALL volume from 2004 through 2014 was calculated based on the number of AYA ALL inductions administered by each facility in our data set. If > 1 facility reported administering chemotherapy, individual records were reviewed to identify the hospital that administered the induction regimen.
Statistical Analysis
Descriptive statistics (frequencies, percentages) characterized baseline patient, hospital, and treatment characteristics by treatment settings and regimens. Differences between pediatric and adult treatment settings and pediatric and adult ALL regimens administered in adult treatment settings were evaluated using the Fisher exact test. Statistical analyses were performed using SAS statistical software (versions 9.3 and 9.4; SAS Institute Inc, Cary, NC); 2-sided P values < .05 were considered to be statistically significant. The current study was approved under the GBACR Institutional Review Board protocol by the Cancer Prevention Institute of California Institutional Review Board.
RESULTS

Patient Characteristics and Treatment Setting
A total of 304 AYA patients with ALL who were diagnosed in the GBA from 2004 through 2014 were identified (see Fig. 1 for the cohort diagram). The treatment setting in which induction chemotherapy was administered was captured for 296 patients (97%); 8 patients for whom the treatment setting could not be discerned were excluded from additional analyses. Treatment occurred in 31 unique facilities. Of these, 2 were exclusively pediatric facilities and Children's Oncology Group member institutions. An additional 8 pediatric facilities that report to the CCR as part of a larger institution were identified by the specialty and practice location of the treating physician. Of these, approximately one-half were Children's Oncology Group member institutions. The remaining 21 treatment facilities were exclusively considered to be adult facilities, 3 of which were NCI-designated cancer centers.
The majority of AYA individuals in the current study (207; 70%) received initial induction therapy in an adult setting (Table 1) . AYA patients treated in the adult setting were older (P<.0001) and were more likely to be non-Hispanic white (P 5 .02) compared with AYA patients treated in the pediatric setting. Patients treated in an adult setting were less likely to be treated at a facility associated with an NCI-designated cancer center (P 5 .042), and more likely to be treated at low-volume AYA ALL centers (P<.0001).
Shifts in Treatment Setting Over Time
For the youngest AYA patients (those aged 15-18 years), the majority received therapy in a pediatric setting (93%), with no significant changes in treatment setting noted over time (Fig. 2) . Older AYA patients (those aged 25-39 years) were exclusively treated in adult settings throughout the decade. For AYA patients aged 19 to 24 years, there was a shift toward ALL treatment increasingly being delivered in pediatric, as opposed to adult, centers over time (P<.0001).
Treatment Regimens Administered to AYA Patients in the Adult Setting
Complete induction regimen data were available for 229 patients in the entire cohort (75%). A total of 89 AYA Among the 207 AYA patients treated in an adult setting, complete induction regimen data were available for 149 (72%); 56 patients (27%) received treatment that could not be clearly identified as a pediatric or adult ALL regimen, and 2 patients died before treatment administration (Fig. 1) . The treatment regimen was increasingly Abbreviations: ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; NCI-CC: National Cancer Institute-designated cancer center, NOS, not otherwise specified; SES: socioeconomic status. a There were 20 lower volume facilities, 7 higher volume facilities, and 1 out-of-region facility without volume calculation. A total of 15 patients who were treated out of region or not treated were excluded.
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Cancer January 1, 2017 induction treatment at an NCI-designated cancer center, and to receive induction treatment at a facility that treated 2 AYA patients with ALL per year (Table 3 ). In the adult setting, the distribution of patient-related variables such as age, race/ethnicity, neighborhood SES, and health insurance status were similar for AYA patients who received a pediatric versus adult ALL regimen.
DISCUSSION
AYA patients with ALL represent a unique population at a crossroads between pediatric and adult oncology. However, the gap between recommended pediatric versus adult approaches to ALL in AYA patients has narrowed through retrospective and prospective research demonstrating that outcomes for AYA patients with ALL are superior when these patients are treated using pediatric-inspired ALL regimens, regardless of the setting in which they are delivered. [1] [2] [3] 5, [7] [8] [9] [10] [11] [12] [13] [14] Although this message has been disseminated throughout the oncology literature and through clinical guideline summaries and practice recommendations internationally and within the United States, 28, 29 the results of the current study, based on a populationbased case series, indicated that as recently as 2014, only a minority of AYA patients with ALL who receive care across a wide variety of adult oncology facilities in Northern California are treated following pediatric ALL regimens.
There are several likely explanations for why the adoption of pediatric-inspired ALL regimens may be slow within the general adult oncology community in the United States. As shown by others and supported in the results presented herein, unlike pediatric ALL, the majority of patients with adult ALL diagnosed in the United States are not treated in highly specialized, high-volume Original Article ALL centers. 16 It is interesting to note that we found that approximately one-third of AYA patients with ALL who were treated in adult settings were cared for at centers that treat 1 AYA patient with ALL per year. Adult oncologists who rarely treat ALL may be less familiar with the literature supporting a pediatric treatment approach for ALL diagnosed in AYA individuals. Furthermore, they also may be less comfortable with the often challenging schedules and drug administration associated with pediatric ALL protocols. In addition, specific toxicities related Abbreviations: ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; NCI-CC: National Cancer Institute-designated cancer center, NOS, not otherwise specified; SES: socioeconomic status. a Excluded 15 patients who were treated out of region or not treated.
to pediatric ALL regimens may be heightened in the AYA population, 30, 31 such as steroid-induced osteonecrosis, hepatotoxicity, and thrombosis related to asparaginase, which, if encountered, may lead to an unwillingness to embark on these intensive ALL regimens in other AYA patients. Additional work is needed to more clearly understand the knowledge gaps and barriers to the use of pediatric-inspired ALL protocols within the diverse US adult oncology community.
In addition to describing oncologist practice patterns, the current study provided a general overview of where AYA patients with ALL are receiving care in the United States. Not surprisingly, AYA individuals aged 18 years were almost entirely treated at pediatric centers, whereas those aged 25 years were universally cared for in adult treatment settings. What is perhaps most interesting is to examine the group of AYA patients aged 19 to 24 years, who are truly at the intersection between teenage years and young adulthood. The data from the current study demonstrate that this group may be increasingly cared for at pediatric centers, or perhaps within AYA programs housed within pediatric centers. Given the small sample size of these patients within our data set, this finding should be confirmed in a larger cohort. Many have advocated for the creation of AYA-specific programs to provide age-specific care and to better address the unique toxicities and psychosocial challenges that face AYA individuals with cancer. 32, 33 Although the data from the current study could not determine care received through AYA specialty programs, others have reported an increased use of pediatric regimens delivered to patients with ALL who are treated at AYA centers. 34 At a minimum, the findings of the current study support the theory that AYA patients with ALL are more likely to receive pediatric ALL regimens at either pediatric centers or at adult centers that treat a higher volume of these patients. Our findings that receipt of a pediatric ALL regimen in the adult setting are associated with NCIcancer center designation and AYA ALL volume is, in part, related to the C10403 study, which was open to accrual from 2008 to 2012. Although this study was open at larger academic cancer centers, it also was open to accrual at community-based cancer centers. Furthermore, the trend toward the use of adult ALL regimens at lower volume AYA ALL facilities continued through 2013 to 2014, thereby supporting the belief that even after closure of this national study there continues to be a variety of approaches to the treatment of ALL in AYA patients. The findings of the current study suggest that the use of pediatric-inspired ALL regimens for AYA patients treated in the adult setting may increase with the opening of another national ALL trial aimed at AYA patients. However, AYA patients treated at low-volume ALL centers often do not have access to cooperative group studies, thereby widening the disparity in treatment approaches between centers caring for AYA patients with ALL.
The intent of the current study was to describe patterns of ALL treatment in AYA individuals with a population-based approach. We used choice of induction regimen as a surrogate for treatment approach. For the majority of patients with ALL, the initial ALL regimen is followed throughout the treatment course; however, clinical circumstances such as refractory disease or transplantation performed at the time of first remission may alter the treatment course over time. We were limited in that not every patient reported to the GBACR had usable induction treatment data, although data capture in >70% of patients was more favorable than anticipated, and the majority of those patients without usable data were treated from 2004 to 2007, when most, if not all, AYA patients with ALL were treated using adult regimens in the adult setting. The sample size in the current study did not allow for multivariate modeling of the independent factors associated with pediatric regimens in the adult setting, which would be of interest. It is important to note that results based on patients in Northern California may not represent AYA patients with ALL or practice patterns across the United States. However, use of a population-based data set enabled us to include AYA patients with ALL with a variety of racial/ethnic and socioeconomic backgrounds, including those who were uninsured, privately insured, and publicly insured. Patients in the current study were treated at 31 hospitals, including small community-based and larger private hospital networks, as well as academic centers, similar to the range of AYA cancer treatment locations across the United States. 35 Consolidation of AYA cancer care in other countries has been described previously. 36, 37 Finally, we did not intend the current study to be a study of outcomes in AYA patients with ALL because there is already an abundance of retrospective and prospective research comparing outcomes for AYA patients with ALL treated with pediatric versus adult regimens [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] [14] 29 ; rather, the objective of the current study was to describe patterns of management of ALL in AYA patients over time to inform clinicians and researchers in the field.
Using a population-based approach with patient facility-level data reported to the GBACR, the results of the current study demonstrate general practice patterns related to the treatment of AYA patients with ALL in the United States over the last decade. The data herein
Original Article indicate that as recently as 2014, AYA patients with ALL were treated with a wide variety of treatment protocols, with the minority being pediatric-inspired ALL regimens. Additional research is needed to determine factors that contribute to treatment selection for AYA patients with ALL by adult oncologists, and to understand barriers to increasing AYA care at higher volume AYA ALL centers.
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